Effect of 0.1% Bromfenac for Preventing Macular Edema after Cataract Surgery in Patients with Diabetes
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: To investigate the effect of 0.1% bromfenac sodium hydrate ophthalmic solution for prevention of macularedema after cataract surgery in patients with diabetes. Methods: A retrospective analysis of 75 patients with diabetes who underwent cataract surgery was performed. Thirty-eight patients (52 eyes) were instilled with 0.1% bromfenac solution (bromfenac group) and 37 patients (46eyes) were not (control group). Results: There were no significant preoperative between-group differences. Compared to the control group,at 1 month after surgery, the bromfenac group showed slightly better best-corrected visual acuity (0.12 ± 0.12vs. 0.32 ± 0.42, p = 0.142), lower central macular thickness (265.58 ± 31.28 vs. 314.15 ± 76.11 μm, p < 0.001),and lower macular volume (8.46 ± 0.60 vs. 9.14 ± 1.53 mm3, p = 0.022). There were no significant differencesbetween the two groups at 4 and 6 months postoperatively (p > 0.05). Mean changes in central macular thicknessshowed significant differences at 1 and 4 months postoperatively (-1.44 ± 11.72 and 10.44 ± 22.48 μm inbromfenac group vs. 47.19 ± 70.24 and 31.69 ± 48.04 μm in control group, p < 0.001 and p = 0.016) and meanchanges in macular volume showed a significant difference at 1 month postoperatively (-0.08 ± 0.47 mm3 inbromfenac group vs. 0.58 ± 1.28 mm3 in control group, p < 0.001). There were no significant differences thereafter(p > 0.05). Conclusions: Treatment with 0.1% bromfenac sodium hydrate ophthalmic solution showed good efficacy forpreventing cystoid macular edema early after cataract surgery in patients with diabetes.
Abstract
Purpose: To investigate the effect of 0.1% bromfenac sodium hydrate ophthalmic solution for prevention of macularedema after cataract surgery in patients with diabetes. Methods: A retrospective analysis of 75 patients with diabetes who underwent cataract surgery was performed. Thirty-eight patients (52 eyes) were instilled with 0.1% bromfenac solution (bromfenac group) and 37 patients (46eyes) were not (control group). Results: There were no significant preoperative between-group differences. Compared to the control group,at 1 month after surgery, the bromfenac group showed slightly better best-corrected visual acuity (0.12 ± 0.12vs. 0.32 ± 0.42, p = 0.142), lower central macular thickness (265.58 ± 31.28 vs. 314.15 ± 76.11 μm, p < 0.001),and lower macular volume (8.46 ± 0.60 vs. 9.14 ± 1.53 mm3, p = 0.022). There were no significant differencesbetween the two groups at 4 and 6 months postoperatively (p > 0.05). Mean changes in central macular thicknessshowed significant differences at 1 and 4 months postoperatively (-1.44 ± 11.72 and 10.44 ± 22.48 μm inbromfenac group vs. 47.19 ± 70.24 and 31.69 ± 48.04 μm in control group, p < 0.001 and p = 0.016) and meanchanges in macular volume showed a significant difference at 1 month postoperatively (-0.08 ± 0.47 mm3 inbromfenac group vs. 0.58 ± 1.28 mm3 in control group, p < 0.001). There were no significant differences thereafter(p > 0.05). Conclusions: Treatment with 0.1% bromfenac sodium hydrate ophthalmic solution showed good efficacy forpreventing cystoid macular edema early after cataract surgery in patients with diabetes.
참고문헌 (47)
- Yonekawa Y, "Pseudophakic cystoid macular edema", Curr Opin Ophthalmol, 23, pp.26~32 (2012)
- Kim SJ, "Optical coherence tomography and cataract surgery", Curr Opin Ophthalmol, 20, pp.46~51 (2009)
- Daien V, "Incidence and characteristics of cystoid macular edema after cataract surgery", Ophthalmology, 123, pp.663~664 (2016)
- Rossetti L, "Medical prophylaxis and treatment of cystoid macular edema after cataract surgery. The results of a meta-analysis", Ophthalmology, 105, pp.397~405 (1998)
- Flach AJ, "The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery", Trans Am Ophthalmol Soc, 96, pp.557~634 (1998)
- Miyake K, "Prostaglandins and cystoid macular edema", Surv Ophthalmol, 47, pp.S203~S218 (2002)
- Kim SJ, "Nonsteroidal anti-inflammatory drugs in ophthalmology", Surv Ophthalmol, 55, pp.108~133 (2010)
- Almeida DR, "Effect of prophylactic nonsteroidal antiinflammatory drugs on cystoid macular edema assessed using optical coherence tomography quantification of total macular volume after cataract surgery", J Cataract Refract Surg, 34, pp.64~69 (2008)
- Kim SJ, "Analysis of macular edema after cataract surgery in patients with diabetes using optical coherence tomography", Ophthalmology, 114, pp.881~889 (2007)
- Brown RM, "Preoperative and postoperative use of nonsteroidal antiinflammatory drugs in cataract surgery", Insight, 21, pp.13~16 (1996)
- Schmidl B, "Laser flare measurement with 3 different nonsteroidal anti-inflammatory drugs after phacoemulsification with posterior chamber lens implantation", Ophthalmologe, 94, pp.33~37 (1997)
- Notivol R, "Treatment of chronic nonbacterial conjunctivitis with a cyclo-oxygenase inhibitor or a corticosteroid. Pranoprofen Study Group", Am J Ophthalmol, 117, pp.651~656 (1994)
- Kraff MC, "Inhibition of blood-aqueous humor barrier breakdown with diclofenac. A f luorophotometric study", Arch Ophthalmol, 108, pp.380~383 (1990)
- Henderson BA, "Safety and efficacy of bromfenac ophthalmic solution(Bromday)dosed once daily for postoperative ocular inflammation and pain", Ophthalmology, 118, pp.2120~2127 (2011)
- Silverstein SM, "Once daily dosing of bromfenac ophthalmic solution 0.09% for postoperative ocular inflammation and pain", Curr Med Res Opin, 27, pp.1693~1703 (2011)
- Russo A, "Topical nonsteroidal anti-inflammatory drugs for macular edema", Mediators Inflamm, 2013, pp.476525~ (2013)
- Schoenberger SD, "Nonsteroidal anti-inflammatory drugs for retinal disease", Int J Inflam, 2013, pp.281981~ (2013)
- 고창현, "당뇨 환자에서 비스테로이드 항염증제 점안이 백내장 수술 후 황반부종 발생에 미치는 효과", 대한안과학회지, 54(3), pp.427~431 (2013), 대한안과학회
- 천보영, "서로 다른 비스테로이드성 항염증제의 백내장수술 후 황반부종 예방 효과 비교", 대한안과학회지, 51(7), pp.935~940 (2010), 대한안과학회
- Shimura M, "Topical bromfenac reduces the frequency of intravitreal bevacizumab in patients with branch retinal vein occlusion", Br J Ophthalmol, 99, pp.215~219 (2015)
- Flaxel C, "Prospective randomized controlled trial of combination ranibizumab(Lucentis)and bromfenac(Xibrom)for neovascular age-related macular degeneration : a pilot study", Retina, 32, pp.417~423 (2012)
- Gomi F, "Topical bromfenac as an adjunctive treatment with intravitreal ranibizumab for exudative age-related macular degeneration", Retina, 32, pp.1804~1810 (2012)
- Zweifel SA, "Retrospective review of the efficacy of topical bromfenac (0.09%) as an adjunctive therapy for patients with neovascular age-related macular degeneration", Retina, 29, pp.1527~1531 (2009)
- Heier JS, "Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema", Ophthalmology, 107, pp.2034~2038 (2000)
- Cho H, "Management of ocular inflammation and pain following cataract surgery : focus on bromfenac ophthalmic solution", Clin Ophthalmol, 3, pp.199~210 (2009)
- Perry HD, "An update on the use of ophthalmic ketorolac tromethamine 0.4%", Expert Opin Pharmacother, 7, pp.99~107 (2006)
- McGhee CN, "Locally administered ocular corticosteroids : benefits and risks", Drug Saf, 25, pp.33~55 (2002)
- Jones J, "Ophthalmic utility of topical bromfenac, a twice-daily nonsteroidal anti-inflammatory agent", Expert Opin Pharmacother, 10, pp.2379~2385 (2009)
- Wielders LH, "Prevention of cystoid macular edema after cataract surgery in nondiabetic and diabetic patients : a systematic review and meta-analysis", Am J Ophthalmol, 160, pp.968~981 (2015)
- Shorstein NH, "Comparative effectiveness of three prophylactic strategies to prevent clinical macular edema after phacoemulsification surgery", Ophthalmology, 122, pp.2450~2456 (2015)
- Kessel L, "Post-cataract prevention of inflammation and macular edema by steroid and nonsteroidal anti-inflammatory eye drops : a systematic review", Ophthalmology, 121, pp.1915~1924 (2014)
- 정현교, "1% 프레드니솔론과 0.1% 브롬페낙 점안액의 백내장 수술 후 낭포황반부종 예방 효과 비교", 대한안과학회지, 57(12), pp.1834~1839 (2016), 대한안과학회
- Kato S, "Influence of phacoemulsification and intraocular lens implantation on the course of diabetic retinopathy", J Cataract Refract Surg, 25, pp.788~793 (1999)
- Baumal CR, "Clinical applications of optical coherence tomography", Curr Opin Ophthalmol, 10, pp.182~188 (1999)
- Ahuja M, "Topical ocular delivery of NSAIDs", AAPS J, 10, pp.229~241 (2008)
- Flach AJ, "Topical nonsteroidal antiinflammatory drugs in ophthalmology", Int Ophthalmol Clin, 42, pp.1~11 (2002)
- Lindstrom R, "The pharmacologic and pathophysiologic rationale for using NSAIDs in ocular inflammatory disease and ocular surgery", Int Ophthalmol Clin, 46, pp.7~11 (2006)
- Farah AE, "Potential therapeutic applications of aspirin and other cyclo-oxygenase inhibitors", Br J Clin Pharmacol, 10, pp.261S~278S (1980)
- Oka T, "Involvement of cyclooxygenase-2 in rat models of conjunctivitis", Curr Eye Res, 29, pp.27~34 (2004)
- Sancilio LF, "The analgesic and anti-inflammatory activity and pharmacologic properties of bromfenac", Arzneimittelforschung, 37, pp.513~519 (1987)
- Waterbury LD, "Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium", Curr Med Res Opin, 22, pp.1133~1140 (2006)
- Kida T, "Pharmacokinetics and efficacy of topically applied nonsteroidal anti-inflammatory drugs in retinochoroidal tissues in rabbits", PLoS One, 9, pp.e96481~ (2014)
- Baklayan GA, "24-hour evaluation of the ocular distribution of(14)C-labeled bromfenac following topical instillation into the eyes of New Zealand White rabbits", J Ocul Pharmacol Ther, 24, pp.392~398 (2008)
- Endo N, "Efficacy of bromfenac sodium ophthalmic solution in preventing cystoid macular oedema after cataract surgery in patients with diabetes", Acta Ophthalmol, 88, pp.896~900 (2010)
- Kim SJ, "Topical nonsteroidal anti-inflammatory drugs and cataract surgery : a report by the American Academy of Ophthalmology", Ophthalmology, 122, pp.2159~2168 (2015)
- Congdon NG, "Corneal complications associated with topical ophthalmic use of nonsteroidal antiinflammatory drugs", J Cataract Refract Surg, 27, pp.622~631 (2001)
- Lin JC, "Corneal melting associated with use of topical nonsteroidal anti-inflammatory drugs after ocular surgery", Arch Ophthalmol, 118, pp.1129~1132 (2000)